^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
IBI-354
i
Other names: IBI-354, IBI354
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Innovent Biologics
Drug class:
Topoisomerase I inhibitor, HER2-targeted antibody-drug conjugate
Related drugs:
1m
CIBI354A101: A First-in-human Study of IBI354 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors (clinicaltrials.gov)
P1/2, N=368, Recruiting, Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting --> Recruiting | Trial completion date: Jul 2025 --> Oct 2025 | Trial primary completion date: Oct 2024 --> Apr 2025
Enrollment open • Trial completion date • Trial primary completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 expression
|
IBI-354
2years
A First-in-human Study of IBI354 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors (clinicaltrials.gov)
P1/2, N=444, Not yet recruiting, Innovent Biologics (Suzhou) Co. Ltd.
New P1/2 trial • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 expression
|
IBI-354
Share via
